Consequences of the COVID-19 pandemic for patients with metabolic diseases
- 25 February 2021
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Nature Metabolism
- Vol. 3 (3), 289-292
- https://doi.org/10.1038/s42255-021-00358-y
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Insulin Treatment Is Associated with Increased Mortality in Patients with COVID-19 and Type 2 DiabetesCell Metabolism, 2020
- Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19JAMA, 2020
- Increased Hepatic ACE2 Expression in NAFL and Diabetes—A Risk for COVID-19 Patients?Diabetes Care, 2020
- Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort studyThe Lancet Diabetes & Endocrinology, 2020
- Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionalsDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020
- The Untold Toll — The Pandemic’s Effects on Patients without Covid-19The New England Journal of Medicine, 2020
- Novel medications inducing adrenal insufficiencyNature Reviews Endocrinology, 2019
- Preoperative steroids triggering diabetic ketoacidosis in the neurosurgical patientJournal of Clinical Anesthesia, 2018
- Brief dexamethasone treatment during acute infection prevents virus-induced autoimmune diabetesClinical Immunology, 2010
- Predisposing Factors for Adrenal InsufficiencyThe New England Journal of Medicine, 2009